Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allergen-specific IgE antibodies recognizing Dermatophagoides pteronyssinus and Dermatophagoides farinae allergens are the primary mediators of house dust mite (HDM) allergy, which is a major driver of perennial allergic rhinitis, allergic conjunctivitis, and allergic asthma. These IgE antibodies are produced by B cells in sensitized individuals and bind with high affinity to Fc epsilon RI receptors on the surface of mast cells and basophils. Upon subsequent exposure to HDM allergens (primarily major allergens like Der p 1, Der p 2, Der f 1, and Der f 2), the allergens cross-link the bound IgE antibodies, triggering cell degranulation and the rapid release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This cascade leads to the clinical symptoms of allergic airway disease.
Therapeutic targeting of these specific IgE antibodies is achieved through allergen immunotherapy (AIT), including sublingual (SLIT) and subcutaneous (SCIT) formulations. Approved drugs such as Odactra, Acarizax, Miticure, and Actair consist of standardized extracts of D. pteronyssinus and D. farinae. These therapies work by gradually exposing the immune system to controlled doses of the allergens, which induces a shift from a pro-inflammatory Th2 response to a regulatory Th1/Treg response. This immunological shift promotes the production of allergen-specific IgG4 'blocking' antibodies that compete with IgE for allergen binding, thereby preventing IgE cross-linking and subsequent mast cell/basophil activation. While highly effective in desensitizing patients and providing long-term disease modification, these therapies carry a boxed warning for severe systemic allergic reactions, including anaphylaxis, requiring careful patient selection and monitoring.
Allergen immunotherapy (AIT) that desensitizes the immune system by inducing allergen-specific IgG4 blocking antibodies, promoting regulatory T and B cells, shifting the immune response from Th2 to Th1, and reducing IgE-mediated mast cell and basophil degranulation.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen-specific IgE antibodies recognizing Dermatophagoides pteronyssinus and Dermatophagoides farinae allergens (HDM sIgE).